APG Asset Management US Inc. Has $2.37 Million Stake in Bristol-Myers Squibb (NYSE:BMY)

APG Asset Management US Inc. increased its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 42.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,897 shares of the biopharmaceutical company's stock after acquiring an additional 12,546 shares during the period. APG Asset Management US Inc.'s holdings in Bristol-Myers Squibb were worth $2,370,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Fairway Wealth LLC bought a new position in Bristol-Myers Squibb during the 4th quarter valued at approximately $28,000. Comprehensive Financial Planning Inc. PA bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $34,000. Westend Capital Management LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $38,000. Tacita Capital Inc purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at approximately $39,000. Finally, M Holdings Securities Inc. purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at about $39,000. Institutional investors own 76.41% of the company's stock.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 1,823 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares in the company, valued at $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.09% of the stock is currently owned by insiders.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BMY. Citigroup increased their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Cantor Fitzgerald upped their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. UBS Group decreased their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday. Finally, Truist Financial lifted their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $57.67.

Bristol-Myers Squibb Trading Up 0.5 %

BMY stock traded up $0.26 during trading on Monday, reaching $50.97. 5,255,001 shares of the stock were exchanged, compared to its average volume of 12,897,272. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The business has a 50 day moving average price of $57.71 and a 200-day moving average price of $56.78. The firm has a market capitalization of $103.71 billion, a price-to-earnings ratio of -11.53, a P/E/G ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, research analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 4.87%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb's payout ratio is currently -56.11%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.